Michelle Gilson, Chief Financial Officer of Arcellx Inc (ACLX, Financial), sold 12,877 shares of the company on June 26, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 6,915 shares of the company.
Arcellx Inc (ACLX, Financial) is a biotechnology firm focused on the discovery, development, and commercialization of innovative cell therapies for the treatment of patients with cancer and autoimmune diseases.
Over the past year, the insider has sold a total of 40,337 shares and has not made any purchases. This recent transaction is part of a broader trend observed at Arcellx Inc, where there have been 20 insider sells and no insider buys over the past year.
On the date of the transaction, shares of Arcellx Inc were trading at $53.7 each. The company's market cap was approximately $2.95 billion.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's financial health and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
